The tumour suppressor ARF is specifically required for p53 activation under oncogenic stress [1] [2] [3] [4] [5] [6] . Recent studies showed that p53 activation mediated by ARF, but not that induced by DNA damage, acts as a major protection against tumorigenesis in vivo under certain biological settings 7, 8 , suggesting that the ARF-p53 axis has more fundamental functions in tumour suppression than originally thought. Because ARF is a very stable protein in most human cell lines, it has been widely assumed that ARF induction is mediated mainly at the transcriptional level and that activation of the ARF-p53 pathway by oncogenes is a much slower and largely irreversible process by comparison with p53 activation after DNA damage. Here we report that ARF is very unstable in normal human cells but that its degradation is inhibited in cancerous cells. Through biochemical purification, we identified a specific ubiquitin ligase for ARF and named it ULF. ULF interacts with ARF both in vitro and in vivo and promotes the lysine-independent ubiquitylation and degradation of ARF. ULF knockdown stabilizes ARF in normal human cells, triggering ARF-dependent, p53-mediated growth arrest. Moreover, nucleophosmin (NPM) and c-Myc, both of which are commonly overexpressed in cancer cells, are capable of abrogating ULF-mediated ARF ubiquitylation through distinct mechanisms, and thereby promote ARF stabilization in cancer cells. These findings reveal the dynamic feature of the ARF-p53 pathway and suggest that transcription-independent mechanisms are critically involved in ARF regulation during responses to oncogenic stress.
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Although recent studies have demonstrated that ARF turnover can occur through ubiquitylation and proteasomal degradation, the identity of the E3 ligase responsible for ARF degradation and its biological significance are still unknown 5, 9 . In accord with published results, we found that proteasome-mediated ARF degradation is severely inhibited in most human tumour cell lines ( Supplementary Fig. 2 ). In particular, although the levels of ARF protein are low in the cells of normal human fibroblast cell lines such as NHF-1, IMR90 and WI-38 (Fig. 1a) , treatment with a proteasome inhibitor markedly stabilized ARF without affecting the messenger RNA levels ( Supplementary Fig. 3 ) in these cells. Moreover, the half-life of ARF is extremely short in normal human fibroblasts (less than 30 min) ( Fig. 1b and Supplementary Fig. 4 ) but increases markedly (to more than 4 h) in the presence of proteasome inhibitors (Fig. 1c) . These data suggest that ARF is very unstable in normal human cells but that its degradation is inhibited in cancerous cells.
Several studies have shown that both the function and stability of ARF are tightly regulated by NPM (refs 10-17) . To elucidate the mechanism of ARF degradation in vivo, we isolated NPM-associated protein complexes from human cells. Mass spectrometric analysis of the NPM protein complexes identified one polypeptide with a potential ubiquitin ligase domain ( Supplementary Fig. 5 ). A fragment of this protein was named as TRIP12 for a binding partner of the thyroid hormone receptor from a yeast two-hybrid screen with undefined function 18 . We have designated this protein as ULF (ubiquitin ligase for ARF) because the experiments described implicate it in ARF ubiquitylation. In addition to a carboxy-terminal HECT domain that potentially catalyses ubiquitylation, the 2,025-residue ULF protein also contains a centrally located WWE motif and an amino-terminal ARM domain (Armadillo/b-catenin-like repeats) (Fig. 1d) . To determine the physiological function of ULF, we examined whether inactivation of endogenous ULF has any effect on the stability of ARF or NPM. To this end, the normal human fibroblast cell line NHF-1 was transfected with either a ULF-specific (ULFRNAi-1) or a control short interfering RNA (siRNA). As shown in Fig. 1e , the levels of endogenous ULF polypeptides were severely decreased after three consecutive transfections with ULF-RNAi-1. Although the levels of NPM were unaffected by ULF ablation, ULF knockdown significantly elevated ARF protein levels. As additional controls, the levels of Ink4a/p16 and c-Myc were not affected by the same treatment. To exclude off-target effects, we also treated cells with two additional ULF siRNAs (ULF-RNAi-2 and ULF-RNAi-3) that recognized different regions of the ULF mRNA. Again, the endogenous levels of ARF protein were increased by ULF knockdown although the mRNA levels for ARF remained unchanged (Fig. 1f) . Similar results were also obtained in other normal human cell lines such as WI-38 and IMR90 ( Supplementary Fig. 6 ). In addition, the half-life of endogenous ARF was extended from less than 30 min to about 4 h by knockdown of ULF (Fig. 1g ). These data demonstrate that ULF is required for ARF degradation in normal human cells.
To validate a role for ULF in regulating ARF stability in vivo, we first tested the interaction between endogenous ARF and ULF proteins. To this end, cell extracts from NHF-1 cells were immunoprecipitated with anti-ULF or with control IgG. As shown in Fig. 2a , ARF was detected in the immunoprecipitates obtained with the anti-ULF antiserum but not in those obtained with control IgG. Conversely, endogenous ULF was readily immunoprecipitated with an ARF-specific monoclonal antibody but not with control antibody. We also examined whether ARF can bind ULF in vitro. As shown in Fig. 2b , 35 S-labelled ULF strongly bound immobilized glutathione S-transferase (GST)-tagged ARF but not GST alone. These data demonstrate that ULF interacts with ARF both in vitro and in vivo.
To examine the physiological consequence of the ULF-ARF interaction in human cells, we evaluated the role of ULF in regulating the ARF-p53 pathway. For this purpose, normal human fibroblast NHF-1 cells were transfected with either control or ULF-specific siRNAs. As shown in Fig. 2c , RNA interference (RNAi)-mediated knockdown of ULF expression significantly increased the levels of endogenous p53. To ascertain whether the ULF-mediated effect on p53 is dependent on ARF, we tested the consequences of ULF knockdown in the absence of ARF. Indeed, p53 activation was markedly diminished in NHF-1 cells on siRNA-mediated depletion of both ULF and ARF (Fig. 2c) , suggesting that the activation of p53 induced by ULF ablation is dependent on ARF. To examine whether ARF induction affects cell growth, we used bromodeoxyuridine (BrdU) staining of newly synthesized DNA to monitor cell proliferation. As shown in Fig. 2d , ULF knockdown significantly decreased the fraction of BrdU-positive cells (from 54% to 19%), but this effect was reversed by concomitant knockdown of ARF. Cell proliferation was also visibly inhibited after similar treatment in ULF-knockdown cells (Fig. 2e) . Moreover, analysis by fluorescenceactivated cell sorting revealed that ULF knockdown induces growth arrest by increasing the proportion of cells in G1 phase (72% versus 55%) and decreasing the proportion of S-phase cells (14% versus 31%) (Fig. 2f) . Again, these effects were reversed by the concomitant knockdown of either endogenous ARF or p53 (Fig. 2f) . These experiments indicate that inactivation of ULF induces ARF stabilization and triggers an ARF-dependent, p53-mediated arrest of cell growth.
To examine the functional relationship between ARF and ULF, we tested whether ULF induces the ubiquitylation of ARF in cells. Western analysis revealed that ARF ubiquitylation levels were induced in a dosage-dependent manner by ULF expression (Fig. 3a) . To validate the importance of its ubiquitin ligase activity, we also made a point mutant of ULF (ULF-M) in which the conserved cysteine residue in the HECT domain was replaced by alanine (C1992A). In the same assay, this mutation completely abrogated ARF ubiquitylation by ULF (Fig. 3a) . We also examined whether ULF promotes ARF ubiquitylation in a purified in vitro system. As shown in Fig. 3b , western blot analysis with an ARF-specific monoclonal antibody revealed that high levels of ubiquitylated ARF were generated by wild-type ULF but not by the catalytically inactive ULF-M. Because the human ARF polypeptide does not contain a lysine residue, these results demonstrate that ULF is a genuine ubiquitin ligase for lysine-independent ubiquitylation of ARF.
Several recent studies have shown that nucleolar localization of ARF induced by NPM overexpression is crucial for ARF stabilization [9] [10] [11] [12] [13] [14] [15] [16] [17] [19] [20] [21] . In particular, whereas NPM levels are very low in normal human fibroblasts, NPM overexpression occurs in many types of human cancer (Supplementary Fig. 7; refs 22, 23 ). As expected, on ectopic expression of wild-type NPM with ARF in human cells, NPM and ARF were co-localized in the nucleoli (Supplementary Fig. 8 ). However, in contrast to ARF, ULF was predominantly present in the nucleoplasm (Fig. 3c) , suggesting that NPM overexpression in cancer cells induces ARF stabilization by keeping ARF away from its nucleoplasmic ubiquitin ligase. Indeed, ULF-dependent polyubiquitylation of ARF was severely inhibited by overexpression of NPM (Fig. 3d) . Moreover, the coding sequences of the NPM gene are mutated in about 35% of primary acute myeloid leukaemias [24] [25] [26] [27] . These NPM mutants (NPM-c), which failed to promote ARF retention in the nucleoli ( Supplementary Fig. 8 ), had no obvious effect on ULFmediated ubiquitylation of ARF (Fig. 3d) .
To validate NPM-mediated effects on the ULF-ARF interaction in vivo, we examined whether NPM knockdown restores the ULFdependent degradation of ARF in cancer cells. To this end, H1299 carcinoma cells were transfected with a NPM-specific siRNA (NPMRNAi), a ULF-specific siRNA (ULF-RNAi), or a control siRNA (control RNAi). As expected, ARF was very stable in H1299 cells and the levels of I P / a n t i-A R F I n p u t I P / c o n t r o l I P / a n t i-U ARF were not markedly affected by ULF depletion (data not shown). However, RNAi-mediated knockdown of NPM expression significantly decreased the levels of endogenous ARF (Fig. 3e) . In particular, this effect was completely reversed by the concomitant knockdown of ULF (Fig. 3e) . To corroborate these results, we also examined the half-life of ARF protein under different treatments. The long half-life of endogenous ARF in H1299 cells was decreased to less than 30 min by NPM depletion but was restored when both NPM and ULF were depleted (Fig. 3f) . To demonstrate more rigorously the specificity of these effects, we included rescue controls for the RNAi depletion experiments. Thus, expression vectors encoding either wild-type ULF or catalytically inactive ULF-C1992A (ULF-M) were designed with a point mutation at the RNAi-1 targeting region to render them resistant to RNAi-1-mediated depletion ( Supplementary Fig. 9 ). We then examined whether RNAiresistant ULF(R) could restore ARF degradation in H1299 cells simultaneously depleted with NPM-RNAi and ULF-RNAi-1. Expression of RNAi-resistant wild-type ULF, but not C1992A-mutant ULF, significantly decreased the levels of ARF protein in these cells (Fig. 3g) , indicating that the ubiquitin ligase activity is required for ULF-mediated ARF degradation. These data show that ULF induces the ubiquitylation and degradation of ARF but this activity is inhibited in these cancer cells because ULF and ARF exist mostly in different subcellular compartments.
Numerous studies indicate that ARF function is markedly induced by oncogenic stress [4] [5] [6] [7] . Although the mRNA levels for ARF are upregulated in cancer cells, the ARF protein is also stabilized in most human tumour cells. Western analysis revealed that a significant amount of endogenous c-Myc, but not Ras or E2F1, was also copurified with the ULF-associated complexes (Fig. 4a) . We further confirmed that ULF interacts with c-Myc both in vitro and in vivo (Supplementary Fig. 10 ). We next examined whether ULF-mediated ARF ubiquitylation is modulated by c-Myc expression. As shown in Fig. 4b , c-Myc expression markedly decreased ULF-dependent ubiquitylation of ARF, although a mutant Myc (1-328) , lacking the ULFbinding domain ( Supplementary Fig. 11 ), failed to do so. Thus, binding between c-Myc and ULF is required for the Myc-mediated effect on ARF ubiquitylation. To investigate further this novel aspect function of c-Myc on ARF, we made a transcriptionally defective c-Myc mutant (Myc-DBR) that lacks the basic region required for DNA binding but retains its ability to interact with ULF (Supplementary Fig. 12 ). Myc-DBR suppressed ULF-mediated ARF ubiquitylation to the same extent as wild-type c-Myc (Fig. 4b) , and the interaction between ARF and ULF was inhibited by expression of either wild-type Myc or Myc-DBR (Fig. 4c) .
Finally, to examine the transcription-independent effects of c-Myc on ARF induction under more physiological settings, we tested whether Myc-DBR expression was sufficient to activate the ARFp53 pathway in normal human cells. Western analysis of the cell extracts revealed that Myc-DBR expression increased the steady-state levels of endogenous ARF in normal human fibroblasts (Fig. 4d) . As expected, expression of the transcription-defective Myc-DBR had no obvious effect on the levels of ARF mRNA (Fig. 4e) but significantly extended the half-life of ARF polypeptides (Fig. 4f) . Moreover, Myc-DBR expression stabilized p53 and induced p21 expression (Fig. 4d) ; conversely, Ink4a/p16 levels were not altered by Myc-DBR. These data show that c-Myc can stabilize ARF by inhibiting the ULF-ARF interaction and that c-Myc-mediated ARF induction is achieved, at least in part, through a transcription-independent mechanism. ULF probably serves in normal cells as a sensor of oncogenic stress that represses ARF/p53 function in unstressed cells but permits transcription-independent induction of the ARF/p53 pathway in cells at risk of malignant transformation. Obviously, downstream lesions in the p53 pathway, such as p53 mutation and Mdm2 amplification, would impair p53 activation [1] [2] [3] [4] [5] [6] . ULF itself is highly expressed in human tumours, including breast cancer and pancreatic cancer, on the basis of the cancer gene expression profile database from Oncomine Research 28, 29 (Supplementary Fig. 13 ). Mechanistically, our findings add a dynamic feature to the ARF regulatory pathway. On damage to DNA, ubiquitylation of p53 is inhibited by post-translational mechanisms that permit the immediate stabilization and activation of p53 (refs 4, 6) . the activation of p53 by genotoxic stress is therefore a rapid process that prevents the further proliferation of cells bearing damaged DNA. In contrast, ARF induction was thought to be a much slower and largely irreversible process that may require epigenetic changes of the ARF gene locus [1] [2] [3] [4] [5] [6] . Our findings significantly modify the current view of ARF regulation by showing that ARF can be activated through a very rapid and potentially reversible process involving ULF-mediated ubiquitylation, reminiscent of the interaction between p53 and Mdm2. We propose that activation of p53 by ARF, representing a critical barrier for oncogenesis 30 , requires both transcription-independent (fast) and transcription-dependent (slow) upregulation of ARF for effectively suppressing tumorigenesis in vivo.
METHODS SUMMARY
Full-length ULF was amplified by PCR from Marathon-Ready HeLa cDNA (Clontech, BD) and subcloned into pcDNA3.1/V5-His-Topo vector (Invitrogen) or pCIN4-Flag-haemagglutinin (HA) expression vector. The epitope-tagging strategy to isolate NPM-containing protein complexes from human cells was performed essentially as described previously 14 . The bound polypeptides from nuclear extracts by anti-Flag antibody-conjugated agarose (Sigma) were eluted with Flag peptide. M2 eluates were then subjected to a second step of affinity purification on anti-HA beads (Sigma). The final eluates from the anti-HA beads with HA peptides were resolved by SDS-PAGE for silver staining or staining analysis with colloidal blue. Specific bands were cut out of the gel and subjected to massspectrometric peptide sequencing. GST pull-downs were performed with recombinant GST-NPM, Myc, ARF or GST control to pull down 35 S-labelled full-length or fragments of ULF. The ablation of ULF was performed by transfection of the NHF-1 cells or the other adhesive cell lines with siRNA duplex oligonucleotides (ULF-RNAi-1 (59-GGUAGUGACUCCACCCAUUUU-39), ULF-RNAi-2 (59-GA ACACAGAUGGUGCGAUAUU-39) and ULF-RNAi-3 (59-GACAAAGACUCAU ACAAUAUU-39)) using Lipofectamine 2000 in accordance with the manufacturer's protocol. NPM RNAi, ARF RNAi, p53 RNAi and control RNAi were used and transfected in accordance with the manufacturer's guidelines. Adenoviruses expressing Myc or c-Myc-DBR were produced by using the AdEasy Adenoviral Vector System kit from Stratagene as described in the manufacturer's manual. The viruses were used to infect NHF-1 cells at 70% confluence. The in vitro and in vivo ubiquitylation assays were performed as described previously, with some modifications 14 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
